SH Pharma Reports Mixed H1 2026: Revenue Rises 4.15%, Net Profit Slips 21.40%, Proposes Cash Dividend

Bulletin Express08-27

Shanghai Pharmaceuticals Holding Co., Ltd. (SH Pharma) released its unaudited interim results for the six months ended 30 June 2026.

Revenue edged up 4.15 % year on year to RMB 147.47 billion, driven by an 8.44 % rise in pharmaceutical manufacturing sales to RMB 13.19 billion and a 3.75 % increase in pharmaceutical services revenue to RMB 134.28 billion.

Net profit attributable to shareholders fell 21.40 % to RMB 3.50 billion. The decline reflects a high comparison base in the prior-year period and lower investment gains; investment income dropped 74.60 % to RMB 0.83 billion. Adjusted for non-recurring items, core net profit improved 17.98 % to RMB 2.48 billion.

Operating cash flow strengthened markedly, climbing to RMB 4.45 billion from RMB 0.99 billion a year earlier. R&D expenditure reached RMB 1.05 billion, representing 7.98 % of manufacturing sales.

Total assets stood at RMB 240.77 billion (+3.27 %), while total liabilities were RMB 147.98 billion, leaving a gearing ratio of 22.36 %. Short-term borrowings amounted to RMB 46.53 billion; long-term borrowings were RMB 3.28 billion.

The Board declared an interim cash dividend of RMB 1.00 per 10 shares, totalling RMB 0.37 billion, equivalent to 10.58 % of first-half net profit attributable to shareholders.

SH Pharma reiterated that no material risks have arisen during the period and confirmed no appropriation of funds by controlling shareholders or connected parties. The results remain unaudited and subject to review.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104967737?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-27 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104967737","market":"hk","top_or_hot":-1,"title":"SH Pharma Reports Mixed H1 2026: Revenue Rises 4.15%, Net Profit Slips 21.40%, Proposes Cash Dividend","media":"Bulletin Express","content":"<p>Shanghai Pharmaceuticals Holding Co., Ltd. (SH Pharma) released its unaudited interim results for the six months ended 30 June 2026.</p>\n<p>Revenue edged up 4.15 % year on year to RMB 147.47 billion, driven by an 8.44 % rise in pharmaceutical manufacturing sales to RMB 13.19 billion and a 3.75 % increase in pharmaceutical services revenue to RMB 134.28 billion.</p>\n<p>Net profit attributable to shareholders fell 21.40 % to RMB 3.50 billion. The decline reflects a high comparison base in the prior-year period and lower investment gains; investment income dropped 74.60 % to RMB 0.83 billion. Adjusted for non-recurring items, core net profit improved 17.98 % to RMB 2.48 billion.</p>\n<p>Operating cash flow strengthened markedly, climbing to RMB 4.45 billion from RMB 0.99 billion a year earlier. R&D expenditure reached RMB 1.05 billion, representing 7.98 % of manufacturing sales.</p>\n<p>Total assets stood at RMB 240.77 billion (+3.27 %), while total liabilities were RMB 147.98 billion, leaving a gearing ratio of 22.36 %. Short-term borrowings amounted to RMB 46.53 billion; long-term borrowings were RMB 3.28 billion.</p>\n<p>The Board declared an interim cash dividend of RMB 1.00 per 10 shares, totalling RMB 0.37 billion, equivalent to 10.58 % of first-half net profit attributable to shareholders.</p>\n<p>SH Pharma reiterated that no material risks have arisen during the period and confirmed no appropriation of funds by controlling shareholders or connected parties. The results remain unaudited and subject to review.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SH Pharma Reports Mixed H1 2026: Revenue Rises 4.15%, Net Profit Slips 21.40%, Proposes Cash Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSH Pharma Reports Mixed H1 2026: Revenue Rises 4.15%, Net Profit Slips 21.40%, Proposes Cash Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-27 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co., Ltd. (SH Pharma) released its unaudited interim results for the six months ended 30 June 2026.</p>\n<p>Revenue edged up 4.15 % year on year to RMB 147.47 billion, driven by an 8.44 % rise in pharmaceutical manufacturing sales to RMB 13.19 billion and a 3.75 % increase in pharmaceutical services revenue to RMB 134.28 billion.</p>\n<p>Net profit attributable to shareholders fell 21.40 % to RMB 3.50 billion. The decline reflects a high comparison base in the prior-year period and lower investment gains; investment income dropped 74.60 % to RMB 0.83 billion. Adjusted for non-recurring items, core net profit improved 17.98 % to RMB 2.48 billion.</p>\n<p>Operating cash flow strengthened markedly, climbing to RMB 4.45 billion from RMB 0.99 billion a year earlier. R&D expenditure reached RMB 1.05 billion, representing 7.98 % of manufacturing sales.</p>\n<p>Total assets stood at RMB 240.77 billion (+3.27 %), while total liabilities were RMB 147.98 billion, leaving a gearing ratio of 22.36 %. Short-term borrowings amounted to RMB 46.53 billion; long-term borrowings were RMB 3.28 billion.</p>\n<p>The Board declared an interim cash dividend of RMB 1.00 per 10 shares, totalling RMB 0.37 billion, equivalent to 10.58 % of first-half net profit attributable to shareholders.</p>\n<p>SH Pharma reiterated that no material risks have arisen during the period and confirmed no appropriation of funds by controlling shareholders or connected parties. The results remain unaudited and subject to review.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02607","symbol_name":"上海医药","start_time":0,"source_url":"","article_id":"1104967737","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104967737","pubTimestamp":1787831009,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (SH Pharma) released its unaudited interim results for the six months ended 30 June 2026. Revenue edged up 4.15 % year on year to RMB 147.47 billion, driven...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02607":"上海医药"},"translate_title":"SH Pharma 报告 2026 年上半年好坏参半：收入增长 4.15%，净利润下滑 21.40%，提议现金股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co., Ltd. (SH Pharma) released its unaudited interim results for the six months ended 30 June 2026.\nRevenue edged up 4.15 % year on year to RMB 147.47 billion, driven by an 8.44 % rise in pharmaceutical manufacturing sales to RMB 13.19 billion and a 3.75 % increase in pharmaceutical services revenue to RMB 134.28 billion.\nNet profit attributable to shareholders fell 21.40 % to RMB 3.50 billion. The decline reflects a high comparison base in the prior-year period and lower investment gains; investment income dropped 74.60 % to RMB 0.83 billion. Adjusted for non-recurring items, core net profit improved 17.98 % to RMB 2.48 billion.\nOperating cash flow strengthened markedly, climbing to RMB 4.45 billion from RMB 0.99 billion a year earlier. R&D expenditure reached RMB 1.05 billion, representing 7.98 % of manufacturing sales.\nTotal assets stood at RMB 240.77 billion (+3.27 %), while total liabilities were RMB 147.98 billion, leaving a gearing ratio of 22.36 %. Short-term borrowings amounted to RMB 46.53 billion; long-term borrowings were RMB 3.28 billion.\nThe Board declared an interim cash dividend of RMB 1.00 per 10 shares, totalling RMB 0.37 billion, equivalent to 10.58 % of first-half net profit attributable to shareholders.\nSH Pharma reiterated that no material risks have arisen during the period and confirmed no appropriation of funds by controlling shareholders or connected parties. The results remain unaudited and subject to review.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104967737","isCrawlerRequest":true}